HUP0103152A3 - Monoclonal antibodies directed against the g3bp protein, and uses - Google Patents

Monoclonal antibodies directed against the g3bp protein, and uses

Info

Publication number
HUP0103152A3
HUP0103152A3 HU0103152A HUP0103152A HUP0103152A3 HU P0103152 A3 HUP0103152 A3 HU P0103152A3 HU 0103152 A HU0103152 A HU 0103152A HU P0103152 A HUP0103152 A HU P0103152A HU P0103152 A3 HUP0103152 A3 HU P0103152A3
Authority
HU
Hungary
Prior art keywords
monoclonal antibodies
directed against
antibodies directed
g3bp protein
g3bp
Prior art date
Application number
HU0103152A
Other languages
English (en)
Original Assignee
Aventis Pharma Sa
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Aventis Pharma Sa filed Critical Aventis Pharma Sa
Publication of HUP0103152A2 publication Critical patent/HUP0103152A2/hu
Publication of HUP0103152A3 publication Critical patent/HUP0103152A3/hu

Links

Classifications

    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/574—Immunoassay; Biospecific binding assay; Materials therefor for cancer
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/574—Immunoassay; Biospecific binding assay; Materials therefor for cancer
    • G01N33/57484—Immunoassay; Biospecific binding assay; Materials therefor for cancer involving compounds serving as markers for tumor, cancer, neoplasia, e.g. cellular determinants, receptors, heat shock/stress proteins, A-protein, oligosaccharides, metabolites
    • G01N33/57488—Immunoassay; Biospecific binding assay; Materials therefor for cancer involving compounds serving as markers for tumor, cancer, neoplasia, e.g. cellular determinants, receptors, heat shock/stress proteins, A-protein, oligosaccharides, metabolites involving compounds identifable in body fluids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/60—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments
    • C07K2317/62—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments comprising only variable region components
    • C07K2317/622—Single chain antibody (scFv)
HU0103152A 1998-06-17 1999-06-17 Monoclonal antibodies directed against the g3bp protein, and uses HUP0103152A3 (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
FR9807617A FR2780062B1 (fr) 1998-06-17 1998-06-17 Anticorps monoclonaux diriges contre la proteine g3bp, et leurs utilisations
PCT/FR1999/001453 WO1999065947A2 (fr) 1998-06-17 1999-06-17 Anticorps monoclonaux diriges contre la proteine g3bp, et leurs utilisations

Publications (2)

Publication Number Publication Date
HUP0103152A2 HUP0103152A2 (hu) 2001-12-28
HUP0103152A3 true HUP0103152A3 (en) 2004-03-01

Family

ID=9527481

Family Applications (1)

Application Number Title Priority Date Filing Date
HU0103152A HUP0103152A3 (en) 1998-06-17 1999-06-17 Monoclonal antibodies directed against the g3bp protein, and uses

Country Status (13)

Country Link
US (1) US7001980B1 (hu)
EP (1) EP1087997B1 (hu)
JP (1) JP2002518001A (hu)
KR (1) KR100694917B1 (hu)
CN (1) CN1213070C (hu)
AT (1) ATE395363T1 (hu)
AU (1) AU764139B2 (hu)
CA (1) CA2331151A1 (hu)
DE (1) DE69938725D1 (hu)
FR (1) FR2780062B1 (hu)
HU (1) HUP0103152A3 (hu)
IL (2) IL139852A0 (hu)
WO (1) WO1999065947A2 (hu)

Families Citing this family (13)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU2001266070A1 (en) * 2000-06-16 2001-12-24 Max-Planck-Gesellschaft Zur Forderung Der Wissenschaften E.V. Method for identifying apoptosis-modified proteins
CN1341644A (zh) * 2000-09-07 2002-03-27 上海博德基因开发有限公司 一种新的多肽——人核内非均－核蛋白32.01和编码这种多肽的多核苷酸
AUPR721101A0 (en) * 2001-08-23 2001-09-13 University Of Queensland, The Nucleic acid and polypeptide linked to breast cancer
EP1514118A2 (en) * 2002-06-20 2005-03-16 EVOTEC Neurosciences GmbH Diagnostic and therapeutic use of ras-gtpase-activating sh3-domain-binding protein 2 (g3bp2) for neurodegenerative diseases
CA2530613A1 (en) * 2003-06-30 2005-01-06 Universite De Lausanne Rasgap derived peptide for selectively killing cancer cells
ES2429407T3 (es) 2006-06-08 2013-11-14 Chugai Seiyaku Kabushiki Kaisha Agente preventivo o remedio para enfermedades inflamatorias
RU2531521C2 (ru) 2007-12-05 2014-10-20 Чугаи Сейяку Кабусики Кайся Антитело против nr10 и его применение
CN102625711A (zh) 2009-09-10 2012-08-01 梅约医学教育与研究基金会 调节去泛素化酶和泛素化多肽的方法和材料
CN101921313B (zh) * 2010-04-07 2012-02-29 武汉凯泰新生物技术有限公司 治疗或预防癌症的多肽或其衍生产品及应用
MX2013009859A (es) 2011-03-01 2014-02-28 Novo Nordisk As Ligandos dr3 antagonicos.
MA43918A (fr) 2015-04-14 2018-12-05 Chugai Pharmaceutical Co Ltd Composition pharmaceutique pour la prã‰vention et/ou le traitement de la dermatite atopique contenant comme principe actif un antagoniste de l'il-31
CN106771258A (zh) * 2017-02-16 2017-05-31 广州赛太特生物医学科技有限公司 一种半乳糖凝集素‑3结合蛋白的检测试剂盒及其方法和应用
TW202128222A (zh) 2019-11-20 2021-08-01 日商中外製藥股份有限公司 含有抗體之製劑

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5402648A (en) 1993-07-01 1995-04-04 Apd Cryogenics Inc. Sealed dewar with separate circulation loop for external cooling at constant pressure
IL116026A (en) * 1994-11-22 2005-08-31 Rhone Poulenc Rorer Sa Peptides capable of linking to the sh3 domain of gap, nucleotide sequences encoding the same, their preparation and uses
US5783186A (en) * 1995-12-05 1998-07-21 Amgen Inc. Antibody-induced apoptosis
US6252050B1 (en) * 1998-06-12 2001-06-26 Genentech, Inc. Method for making monoclonal antibodies and cross-reactive antibodies obtainable by the method

Also Published As

Publication number Publication date
US7001980B1 (en) 2006-02-21
AU764139B2 (en) 2003-08-14
HUP0103152A2 (hu) 2001-12-28
AU4151599A (en) 2000-01-05
FR2780062B1 (fr) 2000-07-28
KR100694917B1 (ko) 2007-03-14
ATE395363T1 (de) 2008-05-15
IL139852A (en) 2006-04-10
EP1087997A2 (fr) 2001-04-04
KR20010052942A (ko) 2001-06-25
IL139852A0 (en) 2002-02-10
WO1999065947A2 (fr) 1999-12-23
CN1213070C (zh) 2005-08-03
CN1305497A (zh) 2001-07-25
EP1087997B1 (fr) 2008-05-14
JP2002518001A (ja) 2002-06-25
DE69938725D1 (de) 2008-06-26
CA2331151A1 (fr) 1999-12-23
WO1999065947A3 (fr) 2000-02-24
FR2780062A1 (fr) 1999-12-24

Similar Documents

Publication Publication Date Title
EP1071458A4 (en) HUMANIZED ANTIBODIES AND ITS USES
EP1073464A4 (en) MONOCLONAL ANTIBODIES WITH REDUCED IMMUNIZABILITY
GB9809839D0 (en) Antibody
IL128406A0 (en) Monoclonal antibodies
AU1462300A (en) Human pan-hcv human monoclonal antibodies
AU2508499A (en) Ligands of the cd47 antigen, agents binding the ligands of the cd47 antigen and uses thereof
GB9603256D0 (en) Antibodies
IL130143A0 (en) Humanized anti-CD11a antibodies
PL311926A1 (en) Anti-alphav-integrinic monoclonal antibodies
GB0029360D0 (en) Humanised antibodies and uses thereof
ZA99452B (en) Antibodies against human IL-12.
GB9911569D0 (en) Antibodies
IL147517A0 (en) Monoclonal antibodies and immunoassay utilizing the same
AU3667399A (en) Monoclonal antibodies specific for anthrax spores and peptides derived from the antibodies thereof
HUP0103152A3 (en) Monoclonal antibodies directed against the g3bp protein, and uses
AU2001241611A1 (en) Adam polynucleotides, polypeptides, and antibodies
AU2452301A (en) Protein methylarginine-specific antibodies
GB9818915D0 (en) Antibodies
HUP0202270A2 (en) Antitumor antibodies, proteins, and uses thereof
GB9828700D0 (en) Antibody
GB9718911D0 (en) Monoclonal antibodies
GB9819411D0 (en) Antibodies
GB9825184D0 (en) Antigen
EP1033402A4 (en) P16 BINDING PROTEINS, GENE OF SUCH PROTEINS AND ANTIBODIES AGAINST THESE PROTEINS
ZA986064B (en) Ancrod-specific monoclonal antibodies, antibody fragments, mixtures or derivatives thereof and their use.

Legal Events

Date Code Title Description
FD9A Lapse of provisional protection due to non-payment of fees